Get started
Author

Alessandro De Toma

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
2020 · Marina Chiara Garassino, Jennifer G Whisenant, et al. · The Lancet Oncology · 621
Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2020 · Fausto Petrelli, Diego Signorelli, et al. · Cancers · 307
PDF
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
2021 · Alessio Cortellini, Massimo Di Maio, et al. · Journal for ImmunoTherapy of Cancer · 160
PDF
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
2022 · Giuseppe Viscardi, Antonino C. Tralongo, et al. · European Journal of Cancer · 158
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
2020 · Alessio Cortellini, Biagio Ricciuti, et al. · Journal for ImmunoTherapy of Cancer · 103
PDF
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
2020 · Alessio Cortellini, Marcello Tiseo, et al. · Cancer Immunology Immunotherapy · 100
PDF
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
2020 · Alessio Cortellini, Alex Friedlaender, et al. · Clinical Lung Cancer · 88
PDF
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
2019 · Arsela Prelaj, Roberto Ferrara, et al. · Cancers · 80
PDF
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
2022 · L. Cantini, G. Mentrasti, et al. · ESMO Open · 69
PDF
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer
2019 · Giulia Galli, Alessandro De Toma, et al. · Lung Cancer · 69
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
2021 · G.L. Banna, A. Cortellini, et al. · ESMO Open · 61
PDF
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer
2018 · Ilaria Trestini, Luisa Carbognin, et al. · Critical Reviews in Oncology/Hematology · 61
PDF
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
2020 · Giuseppe Luigi Banna, Diego Signorelli, et al. · Translational Lung Cancer Research · 60
PDF
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration
2020 · Jennifer G. Whisenant, Annalisa Trama, et al. · Cancer Cell · 59
PDF
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
2021 · Arsela Prelaj, Achille Bottiglieri, et al. · European Journal of Cancer · 58
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
2021 · Alessio Cortellini, Andrea De Giglio, et al. · Thoracic Cancer · 50
PDF
Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.
2020 · Leora Horn, Jennifer G. Whisenant, et al. · Journal of Clinical Oncology · 50
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort
2019 · Giulio Metro, Alfredo Addeo, et al. · Journal of Thoracic Disease · 47
PDF
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
2023 · Arsela Prelaj, Edoardo Gregorio Galli, et al. · Frontiers in Oncology · 46
PDF
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab
2020 · Alex Friedlaender, Giulio Metro, et al. · Acta Oncologica · 39
PDF
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers
2020 · Riccardo Lobefaro, Giuseppe Viscardi, et al. · Lung Cancer · 37
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
2021 · Sebastiano Buti, Melissa Bersanelli, et al. · European Journal of Cancer · 35
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy
2022 · Arsela Prelaj, Mattia Boeri, et al. · Cancers · 33
PDF
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
2021 · Alessio Cortellini, Katia Cannita, et al. · European Journal of Cancer · 33
PDF
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines
2023 · Claudia Proto, Sara Manglaviti, et al. · Journal of Thoracic Oncology · 32
PDF
Works count: 98
Citation count: 2,844
H-index: 27
I10-index: 41
Year
Topic
Type